VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES
The effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survival, which is around 2–4 months. Targeted therapy...
Main Authors: | D. R. Naskhletashvili, V. A. Gorbunova, A. Kh. Bekyashev, L. V. Demidov, G. Yu. Kharkevich, S. M. Banov, I. V. Samoylenko, K. А. Baryshnikov, K. V. Orlova, I. А. Utyashev, N. N. Petenko, I. G. Markina, E. A. Moskvina, S. V. Medvedev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-04-01
|
Series: | Opuholi Golovy i Šei |
Subjects: | |
Online Access: | https://ogsh.abvpress.ru/jour/article/view/248 |
Similar Items
-
Role of vemurafenib in the treatment of disseminated skin melanoma
by: L V Demidov, et al.
Published: (2013-06-01) -
Successful use of vemurafenib in a patient with resistant hairy cell leukemia
by: E S Urnova, et al.
Published: (2013-07-01) -
Vemurafenib resistant melanoma cells acquire mesenchymal stem cell-like properties
by: A. A. Vartanian, et al.
Published: (2019-12-01) -
Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01) -
Vemurafenib-induced bilateral facial palsy
by: FNU Shailesh, et al.
Published: (2014-01-01)